Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. RAAS inhibitors are cornerstones of CKD treatment. SGLT-2 inhibitors are emerging as the next standard-of-care therapy for the treatment of CKD. AstraZeneca’s Farxiga and Eli Lilly’s Jardiance are approved for treatment of CKD regardless of diabetes status. Johnson & Johnson’s Invokana is approved for treatment of diabetic kidney disease, a subpopulation of CKD. The renoprotective benefits demonstrated by SGLT-2 inhibitors in different dedicated CKD outcomes trials increased the popularity of this class among U.S. nephrologists. In 2021, the FDA approved Bayer’s Kerendia, a novel selective nonsteroidal MRA, for the treatment of CKD patients with type 2 diabetes. Kerendia is gradually garnering patient share among diabetic kidney disease patients. This report analyzes the dynamics of the CKD therapy market, with focus on treatment strategies for CKD patients in different disease stages and factors that influence treatment decisions.
Questions answered
Product description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.